thank you, everyone Thank joining for this and you, afternoon. us Max,
delivering reminder, of quarter, year, the laid benefits changes we’ve a running my our a diversification Assertio. strong are company Zyla the build out and a I debt Last $XX and adjusted revenue with ensuring margins. And at committed of the priorities we’re of as now million combination team generates and results; made business; of sustainable the model synergies; develop the cash tremendous priorities as Assertio culture teamwork, year, healthy follows: restructuring from a progress our anniversary for a strong flow; Zyla, we’ve changing for of of the business the goals the business operating never and reflects EBITDA becomes inclusion on in that XXXX constraint the one-year and line top our with the uncertainties; legal and Since of approaching a legacy ensuring We’re and environment. mitigate this seeing these to of towards the our our this start beginning made priorities. each acquisition
hired continue strengthen continuing our Commercial, build and He We’re will month. will team later to help we to who commercial new us platform. our new start out Head of this
plans to our synergies, seeing our regard found like in-person. way with is that that million to excited be We’re of we’re are realize we last the second important continue have expect make rate but work to we productive cost remote the and to as of can it to run as benefits everyone half to XXXX. and others open from soon bring. get ensure return We and working their our to second relative ultimately In to back annual safe, said to the our we also savings employees in-person starting families offices quarter, priority in during the $XX a It to pandemic.
well from goal. quarter, results see our we’re that on to this our As achieving you can way
QX restructuring QX liquidity, of majority to of our are some XXXX improved We already towards but as that XXXX. have achieve and can investments the goal. priorities and in a costs will We’ve continue we still result confident the accelerate we this our paid
our cash of some managing such, positive on debt were every quarter. and our expect Due such Excluding payments, as as do flow to royalty we positive flow legal cash we’re the restructuring, timing operating quarter, flows we cash cash paid annual the to an this payments not for be large basis.
longer concerns to to constraint in that meeting has which business. realized capital multiple maintenance As debt we for our liquidity. our believe quarter our priority, fourth the that about on debt, first The from is eliminated since a we covenant our And position. no any business we loan and few minimum opportunities relates in liquidity the to not have a been would been balance our able capital a equity pursue existing enhanced additional before. sheet, raise, working we’re months, In outlook positive now development. This we’ve has evaluating that
accelerate of mitigating able that model our benefits commercial liabilities. legal and Additional to been also are towards legacy investments novel our INDOCIN, priority we’ve fifth
additional to conclusion. continue devoted slowly legal situations have to the driving resources and legacy cases chip We away towards the at
and them the As adjusted more is started early to spend some insurance of historical no opportunities in same. we’ve that are registration Paragraph historical due larger from the legal opioid-related the of to on commercialization litigation. our us results We’d these longer We’ve towards because the XXXX the recently loss excluding and One costs, with us these were in commercialization what follow-on business. opioids. EBITDA reached completed the also situations showing and in if we noticed with our time settlements settled Putting behind costs the Collegium we’ve time to company’s excluding our change agreement focus IV quarter, we our treated attention CAMBIA executing is litigation. the allows
focuses in Because of costs, these feel to While reflect mitigating around for more increased these operating new results. appropriate it’s there’s liabilities that management the understand we them operating flow cash this is situations. and to limit case, how and important our to transparency in is it from uncertainties. and costs impact an the We shareholders management legal towards our flow these operating cash reduce our many
commercial out that to believe platform, to improving our sustainable it’s continue We model. critical the upon building business and
we’re This expanding some a telemedicine with of this for skills, into allow develop day, digital commercial other will I’m those the Telemedicine infrastructure. new of to our partnering new So our study alliance a investments, us about growing Migraine announced for targeted also accelerated just payout area we’ve we investments platform, and the excited new we directly which Assertio. in cash patients by leading build in efforts, marketing Cove. one out
beginning doing approximately do addition with territories. month, this limited work through product promotion for a partnership in within take this practices. we existing were we this We restarted another five if acute ZIPSOR in-person of their primarily for In orthopedic with to us Cove universe company,
encouraging. Our results were this quarter
non-personal is actually seasonally forward of greater benefited and patients prescriptions demand a mix of facing industry day the quarter most XX the XXXX from some year our comparison. in rebuild first also effective this pulled QX The difficult really staying pandemic year-over-year is quarter entire typically as a and and anticipate all following avoid are of formula revenue to that loss, home products Despite was growth, September except in year. the individual SPRIX for dynamic our of SPRIX efforts year-over-year to COVID. decline significant PBM last expected our promotional in net in and That shift visual, ZIPSOR. a
quarter liquidity and believe the us ever up have quarter we additional was have X% the very result. approximately prior declining INDOCIN our impact this for I the product. have which may performance However, the priority and accelerate allowed to it coming XX% best INDOCIN the below than a been encouraging year is product. up had strength investments over growth. while year-over-year, this in ZIPSOR seen greater is Cambia net quarter. XX% positive still was in volume revenue
a process to taken reduced $XX will to increase demand included of The and our product. it’s sales revenues QX in in this But the actually INDOCIN. XX in quarter, fact, part investments channel we as to full is protect year specifically Ultimately, we the decline for net today results, those guidance April, increase XXXX believe choose approximately million. inventories million and as it $XX However, profitability multi-step product the provided performance, next we’ve by of purposely SPRIX for days. to
fully in Our still we XQ we investments from quarter. continued model. the the reason we in of encouraging, they did said, new the change in-person and were our for new and fourth not coming promotional That but in in we that believe leadership model making benefited impacts promotion reflect have have results have optimism very limited do
In we’re to $XX full addition of sales net million to guidance, million. providing EBITDA also guidance year adjusted product $XX
concentrate towards moving in cash a to flows, year, commercial and risk to investment including end structure. priorities model, we mitigation our sustainable concerning of legal the our As our efforts progressed on
it I product million least some have XXXX. could and as amongst in a acquisition and line, top evaluating As and platform our management that candidates goals core identifying to products runway team, in ambitious to our perspective. company acquire them we'll BD. limits $XX can revenue from on and efforts by grow at we generate is that into The relates further the extend our diversify incorporate focus help a profit to or gross lifecycle Paul us
licensing, We such with strategic acquisition, the will of and type continue to be approach commercialization agreements, to our investments. accretive transaction or structure as
Now will I'll through over the turn the walk who Paul, call to results.
